SNRIs in the management of acute major depressive disorder

Journal of Clinical Psychiatry

Volumn 65, Issue SUPPL. 17, 2004, Pages 11-18

  Zajecka, John M ^a   Albano, Dominick ^b  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENERGIC RECEPTOR AFFECTING AGENT; ANTIDEPRESSANT AGENT; CYCLOHEXANOL DERIVATIVE; DULOXETINE; PLACEBO; SEROTONIN UPTAKE INHIBITOR; THIOPHENE DERIVATIVE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

ACUTE DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; HUMAN; MAJOR DEPRESSION; PSYCHOLOGICAL ASPECT; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; REVIEW; TREATMENT OUTCOME;

ACUTE DISEASE; ADRENERGIC UPTAKE INHIBITORS; ANTIDEPRESSIVE AGENTS; ANTIDEPRESSIVE AGENTS, TRICYCLIC; CYCLOHEXANOLS; DEPRESSIVE DISORDER, MAJOR; HUMANS; PLACEBOS; RANDOMIZED CONTROLLED TRIALS; RECURRENCE; SEROTONIN UPTAKE INHIBITORS; THIOPHENES; TREATMENT OUTCOME;

EID: 16644383867     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (68)

1. Kessler RC, McGonagle KA, Zhao S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: results from the National Comorbidity Survey. Arch Gen Psychiatry 1994;51:8-19
2. World Health Organization. The World Health Report 2001 - Mental Health: New Understanding, New Hope. Available at http://www.who.int/whr/2001/en. Accessed June 2004
3. Greenberg PE, Leong SA, Birnbaum HG, et al. The economic burden of depression with painful symptoms. J Clin Psychiatry 2003;64(suppl 7): 17-23
4. Wells KB, Stewart A, Hays RD, et al. The functioning and well-being of depressed patients: results from the Medical Outcomes Study. JAMA 1989;262:914-919
5. Lustman PJ, Anderson RJ, Freedland KE, et al. Depression and poor glycemic control: a meta-analytic review of the literature. Diabetes Care 2000;23:934-942
6. Everson SA, Roberts RE, Goldberg DE, et al. Depressive symptoms and increased risk of stroke mortality over a 29-year period. Arch Intern Med 1998;158:1133-1138
7. Vaccarino V, Kasl SV, Abramson J, et al. Depressive symptoms and risk of functional decline and death in patients with heart failure. J Am Coll Cardiol 2001;38:199-205
8. Mueller TI, Leon AC, Keller MB, et al. Recurrence after recovery from major depressive disorder during 15 years of observational follow-up. Am J Psychiatry 1999;156:1000-1006
9. Kendler KS, Thornton LM, Gardner CO. Stressful life events and previous episodes in the etiology of major depression in women: an evaluation of the "kindling" hypothesis. Am J Psychiatry 2000;157: 1243-1251
10. Judd LL, Paulus MJ, Schettler PJ, et al. Does incomplete recovery from first lifetime major depressive episode herald a chronic course of illness? Am J Psychiatry 2000;157:1501-1504
11. Ohayon MM, Schatzberg AF. Using chronic pain to predict depressive morbidity in the general population. Arch Gen Psychiatry 2003;60:39-47
12. Simon GE. Long-term prognosis of depression in primary care. Bull World Health Organ 2000;78:439-445
13. American Psychiatric Association. Practice Guidelines for the Treatment of Patients With Major Depressive Disorder [Revision]. Am J Psychiatry 2000;157(suppl 4):1-45
14. Clinical Practice Guideline Number 5: Depression in Primary Care, vol 2: Treatment of Major Depression. Rockville, Md: US Dept Health Human Services, Agency for Health Care Policy and Research; 1993. AHCPR publication 93-0551
15. Walsh BT, Seidman SN, Sysko R, et al. Placebo response in studies of major depression: variable, substantial, and growing. JAMA 2002;287: 1840-1847
16. Thase ME. How should efficacy be evaluated in randomized clinical trials of treatments for depression? J Clin Psychiatry 1999;60(suppl 4):23-31
17. Khan A, Warner HA, Brown WA. Symptom reduction and suicide risk in patients treated with placebo in antidepressant clinical trials: an analysis of the Food and Drug Administration database. Arch Gen Psychiatry 2000;57:311-317
18. Thase ME. Comparing the methods used to compare antidepressants. Psychopharmacol Bull 2002;36:4-17
19. Danish University Antidepressant Study Group. Citalopram: clinical effect profile in comparison with clomipramine: a controlled multicenter study. Psychopharmacology (Berl) 1986;90:131-138
20. Danish University Antidepressant Group. Paroxetine: a selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect than clomipramine in a controlled multicenter study. J Affect Disord 1990;18:289-299
21. Nelson JC, Mazure CM, Jatlow PI, et al. Combining norepinephrine and serotonin reuptake inhibition mechanisms for treatment of depression: a double-blind, randomized study. Biol Psychiatry 2004;55:296-300
22. Anderson IM, Tomenson BM. The efficacy of selective serotonin reuptake inhibitors in depression: a meta-analysis of studies against tricyclic antidepressants. J Psychopharmacol 1994;8:238-249
23. Anderson IM. SSRIs versus tricyclic antidepressants in depressed inpatients: a meta-analysis of efficacy and tolerability. Depress Anxiety 1998;7(suppl 1):11-17
24. Anderson IM. Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability. J Affect Disord 2000;58:19-36
25. Tzanakaki M, Guazzelli M, Nimatoudis I, et al. Increased remission rates with venlafaxine compared with fluoxetine in hospitalized patients with major depression and melancholia. Int Clin Psychopharmacol 2000;15: 29-34
26. Clerc GE, Ruimy P, Verdeau-Palles J. A double-blind comparison of venlafaxine and fluoxetine in patients hospitalized for major depression and melancholia. The Venlafaxine French Inpatient Study Group. Int Clin Psychopharmacol 1994;9:139-143
27. Poirier MF, Boyer P. Venlafaxine and paroxetine in treatment-resistant depression: double-blind, randomised comparison. Br J Psychiatry 1999; 175:12-16
28. Thase ME, Entsuah AR, Rudolph RL. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiatry 2001;178:234-241
29. Nemeroff CB, Entsuah AR, Willard L, et al. Venlafaxine and SSRIs: pooled remission analysis [abstract]. Eur J Neuropsychopharmacol 2003;13:S255.
30. Smith D, Dempster C, Glanville J, et al. Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: a meta-analysis. Br J Psychiatry 2002;180:396-404
31. Detke MJ, Lu Y, Goldstein DJ, et al. Duloxetine, 60 mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial. J Clin Psychiatry 2002;63:308-315
32. Detke MJ, Lu Y, Goldstein DJ, et al. Duloxetine 60 mg once daily dosing versus placebo in the acute treatment of major depression. J Psychiatr Res 2002;36:383-390
33. Nemeroff CB, Schatzberg AF, Goldstein DJ, et al. Duloxetine for the treatment of major depressive disorder. Psychopharmacol Bull 2002; 36:106-132
34. Thase ME, Lu Y, Joliat M, et al. Remission in placebo controlled trials of duloxetine with an SSRI comparator [poster]. Presented at the 156th annual meeting of the American Psychiatric Association; May 17-22, 2003; San Francisco, Calif
35. Leon AC. Measuring onset of antidepressant action in clinical trials: an overview of definitions and methodology. J Clin Psychiatry 2001; 62(suppl 4):12-16
36. Nelson JC, Mazure CM, Bowers MB Jr, et al. A preliminary, open study of the combination of fluoxetine and desipramine for rapid treatment of major depression. Arch Gen Psychiatry 1991;48:303-307
37. Behnke K, Sogaard J, Martin S, et al. Mirtazapine orally disintegrating tablet versus sertraline: a prospective onset of action study. J Clin Psychopharmacol 2003;23:358-364
38. Entsuah R, Derivan A, Kikta D. Early onset of antidepressant action of venlafaxine: pattern analysis in intent-to-treat patients. Clin Ther 1998;20:517-526
39. Guelfi JD, White C, Hackett D, et al. Effectiveness of venlafaxine in patients hospitalized for major depression and melancholia. J Clin Psychiatry 1995;56:450-458
40. Wohlreich MM, Brannan SK, Mallinckrodt CH, et al. Onset of improvement in emotional and painful physical symptoms of depression with duloxetine treatment. Presented at the 16th annual congress of the European College of Neuropsychopharmacology; September 20-24, 2003; Prague, Czech Republic
41. Brannan SK, Mallinckrodt CH, Detke MJ, et al. Assessing onset of action in clinical trials of duloxetine 60 mg QD [poster]. Presented at the 43rd annual meeting of the New Clinical Drug Evaluation Unit; May 27-30, 2003; Boca Raton, Fla
42. Goldstein D, Lu IL, Detke M, et al. Effects of duloxetine on painful physical symptoms associated with depression. Psychosomatics 2004;45:17-28
43. Entsuah R, Zhang J. Rates of complete somatic symptom resolution among depressed patients treated with venlafaxine or SSRIs [poster]. Presented at the 24th annual meeting of the Collegium Internationale Neuropsychopharmacologicum; June 20-24, 2004; Paris, France
44. Entsuah R, Zhang J. Rates of complete symptom resolution among patients treated with venlafaxine or SSRIs [poster]. Presented at the 24th annual meeting of the Collegium Internationale Neuropsychopharmacologicum; June 20-24, 2004; Paris, France
45. Entsuah R. Complete remission of individual symptoms of depression: a comparison of venlafaxine, SSRIs, and placebo [poster]. Presented at the 24th annual meeting of the Collegium Internationale Neuropsychopharmacologicum; June 20-24, 2004; Paris, France
46. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision. Washington, DC: American Psychiatric Association; 2000
47. Kroenke K, Spitzer RL, Williams JB, et al. Physical symptoms in primary care: predictors of psychiatric disorders and functional impairment. Arch Fam Med 1994;3:774-779
48. Kroenke K. Patients presenting with somatic complaints: epidemiology, psychiatric comorbidity and management. Int J Methods Psychiatr Res 2003;12:34-43
49. Simon GE, VonKorff M, Piccinelli M, et al. An international study of the relation between somatic symptoms and depression. N Engl J Med 1999;341:1329-1335
50. Bair MJ, Robinson RL, Eckert GJ, et al. Impact of pain on depression treatment response in primary care. Psychosom Med 2004;66:17-22
51. Paykel ES, Ramana R, Cooper Z, et al. Residual symptoms after partial remission: an important outcome in depression. Psychol Med 1995;25: 1171-1180
52. Barkin RL, Fawcett J. The management challenges of chronic pain: the role of antidepressants. Am J Ther 2000;7:31-47
53. Rowbotham MC, Goli V, Kunz NR, et al. Venlafaxine extended release in the treatment of painful diabetic neuropathy: a double-blind, placebo-controlled study. Pain 2004;110:697-706
54. Grothe DR, Scheckner B, Albano D. Treatment of pain syndromes with venlafaxine. Pharmacotherapy 2004;24:621-629
55. Bendtsen L, Jensen R. Mirtazapine is effective in the prophylactic treatment of chronic tension-type headache. Neurology 2004;62: 1706-1711
56. Brannon GE, Stone KD. The use of mirtazapine in a patient with chronic pain. J Pain Symptom Manage 1999;18:382-385
57. Arnold LM, Lu Y, Crofford LJ, et al. A double-blind, multicenter trial comparing duloxetine to placebo in the treatment of fibromyalgia with or without major depressive disorder. Presented at the 42nd annual meeting of the American College of Neuropsychopharmacology; December 7-11, 2003; San Juan, Puerto Rico. Abstract 117
58. Goldstein DJ, Lu Y, Iyengar S, et al. Duloxetine in the treatment of the pain associated with diabetic neuropathy [poster]. Presented at the 156th annual meeting of the American Psychiatric Association; May 17-22, 2003; San Francisco, Calif
59. Wernicke JF, Lu Y, D'Souza DN, et al. Duloxetine at doses of 60 mg QD and 60 mg BID is effective treatment of diabetic neuropathic pain. Presented at the 157th annual meeting of the American Psychiatric Association; May 1-5, 2004; New York, NY
60. Dunner DL, Goldstein DJ, Mallinckrodt C, et al. Duloxetine in treatment of anxiety symptoms associated with depression. Depress Anxiety 2003;18:53-61
61. Rudolph RL, Fabre LF, Feighner JP, et al. A randomized, placebo-controlled, dose-response trial of venlafaxine hydrochloride in the treatment of major depression. J Clin Psychiatry 1998;59:116-122
62. Mehtonen O-P, Søgaard J, Roponen P, et al. Randomized, double-blind comparison of venlafaxine and sertraline in outpatients with major depressive disorder. J Clin Psychiatry 2000;61:95-100
63. Cymbalta [package insert]. Indianapolis, Ind: Eli Lilly and Company; 2004
64. Moller HJ, Glaser K, Leverkus F, et al. Double-blind, multicenter comparative study of sertraline versus amitriptyline in outpatients with major depression. Pharmacopsychiatry 2000;33:206-212
65. Thase ME, for the Venlafaxine XR 209 Study Group. Efficacy and tolerability of once-daily venlafaxine extended release (XR) in outpatients with major depression. J Clin Psychiatry 1997;58:393-398
66. Benattia I, Musgnung J, Graepel J. Remission rates among depressed patients treated with venlafaxine XR or SSRIs using treatment algorithms [poster]. Presented at the 157th annual meeting of the American Psychiatric Association; May 1-5, 2004; New York, NY
67. Effexor [package insert]. Philadelphia, Pa: Wyeth Laboratories; 2002
68. Goldstein DJ, Mallinckrodt C, Lu Y, et al. Duloxetine in the treatment of major depressive disorder: a double-blind clinical trial. J Clin Psychiatry 2002;63:225-231